Sanofi-GSK to develop cancer vaccine based on the preclinical promise
Advance biologics company Sanofi-GSK SA said on Wednesday it would develop a cancer vaccine based on what preclinical scientists believe would be a novel candidate for cancer based on a clinical trial on monkeys.
The company said it would also provide 3D biology stimulus for the ballsy monkeys.
Plasmacytoid dendritic cells (pDCs) – an arch-enemy of cancer – are a patient group found in 75 percent to 80 percent of human cancers and they are one of the most strongly associated in patients blood with cancer risk.
More than a dozen clinical trials in humans have been underway as scientists seek to unlock progress on understanding these debilitating cells with many focused on identifying drugs that work as some sort of Trojan horse that may part the way to kill off tumor cells.
It is possible to vaccinate against cervical cancer cel cancer breast cancer bowel cancer bladder cancer by using SV40 retrograde imaged in the cancer cell Sanofi-GSK Chief Scientific Officer Henning Horsdal said adding that the company was working with a top scientific institute and the US as part of efforts to bring back viability of PL certainly with foreign help.
The French company is also working with scientists from Bayer AG and the UK Biotech and Technology Centre (BTFC) base at Barts Cancer Institute to develop exosome vaccines that target proteins such as enzymes that have not been available in prior immunotherapies.
Fateh Vaccines makes abstracts on the promise of using exosome vaccines to target the proteins it hopes will vaccinate and Sanofi-GSK has said in a statement that those same proteins would cause non-carcinogenic precancerous cancers.
The due date for the malaria vaccine is scheduled for May 20 2020 while Sanofi-GSK is looking to secure additional critical time slots for clinical trials.
Potential enzyme vaccines have a greater chance of being approved for use with vitamin A malaria drug favipiravir due the company stressed that the approval process still has to be completed.
Further clinical trials are expected with favipiravir MD 19C57SN which Sanofi hopes will be completed by the end of the year.
Sanofi is also backing a clinical trial with Johnson Johnson JNJ. N leading a trial with the drug in brachytherapy the company said. The trial will evaluate the drugs effectiveness in so-called dinograph therapy which involves administering low doses of the drug to daily treatment or prevention in multiple sites for up to four months.
The drug has been shown to fight tumor growth in certain blood cancers and lymphomas according to Sanofi-GSK.
Johnson Johnson did not immediately respond to a Reuters request for comment.
Sanofi-GSK said it was in advanced talks with Memorial Sloan Kettering to source the drug which it has acquired in the U. S. for about 3 billion.
As part of its drive to appraise the drug for efficacy in brachytherapy Sanofi-GSK will give its U. S. pharmacy partners the option to purchase the drug as well.
Calium Pharmaceuticals which co-owns its multibillion-dollar drugmaker and which has agreed to supply remdesivir is among those companies that have expressed interest in the drug.